Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Diamedica Therapeutics Inc
(NQ:
DMAC
)
4.280
-0.080 (-1.83%)
Streaming Delayed Price
Updated: 11:57 AM EDT, Oct 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Diamedica Therapeutics Inc
< Previous
1
2
3
4
5
Next >
DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia
October 09, 2024
From
DiaMedica Therapeutics Inc.
Via
Business Wire
This Fastenal Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
October 07, 2024
Via
Benzinga
DiaMedica Therapeutics Upcoming Conference Participation
September 04, 2024
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DMAC Stock Earnings: DiaMedica Therapeutics Beats EPS for Q2 2024
August 07, 2024
DMAC stock results show that DiaMedica Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Recap: DiaMedica Therapeutics Q4 Earnings
March 19, 2024
Via
Benzinga
Earnings Outlook For DiaMedica Therapeutics
November 10, 2023
Via
Benzinga
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results
August 07, 2024
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics to Provide a Business Update and Report Second Quarter 2024 Financial Results August 8, 2024
August 01, 2024
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia
July 11, 2024
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics Announces Closing of $11.8 Million Private Placement
July 01, 2024
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics Announces $11.8 Million Private Placement
June 26, 2024
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia
June 26, 2024
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DMAC Stock Earnings: DiaMedica Therapeutics Beats EPS for Q1 2024
May 08, 2024
DMAC stock results show that DiaMedica Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results
May 08, 2024
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024
May 02, 2024
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
April 17, 2024
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DMAC Stock Earnings: DiaMedica Therapeutics Meets EPS for Q4 2023
March 19, 2024
DMAC stock results show that DiaMedica Therapeutics met analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results
March 19, 2024
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference
January 29, 2024
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer
January 22, 2024
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results
November 13, 2023
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics to Attend the 14th Annual Craig-Hallum Alpha Select Conference November 16, 2023
November 09, 2023
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update November 14, 2023
November 06, 2023
From
DiaMedica Therapeutics Inc.
Via
Business Wire
Earnings Scheduled For November 13, 2023
November 13, 2023
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
October 25, 2023
Pre-market stock movers are a hot topic on Wednesday and we're offering all the details that investors need to know about this morning.
Via
InvestorPlace
DiaMedica Therapeutics Announces the Appointment of Ambarish Shah, Ph.D. as Chief Technology Officer
September 12, 2023
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics to Participate at Lake Street’s 7th Annual Best Ideas Growth Conference
September 06, 2023
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2023 Financial Results
August 14, 2023
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics to Report Second Quarter 2023 Financial Results and Provide a Business Update August 15, 2023
August 08, 2023
From
DiaMedica Therapeutics Inc.
Via
Business Wire
DiaMedica Therapeutics to Attend the American Academy of Neurology Summer Conference
July 18, 2023
From
DiaMedica Therapeutics Inc.
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.